DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for poster presentations at the AACR-NCI-EORTC International Conference from Oct. 22-26 at the Moscone Center in San Francisco.
The poster presentations will focus on data concerning many of SuperGen's current oncology programs including the lead clinical compound, MP470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.
In addition to the poster presentations listed below, data on SuperGen's hypomethylating agent, S110, will be presented by Dr. Peter A. Jones on Wednesday, Oct. 24 at 8:00 a.m. in Plenary Session 3: Epigenetic Targets.
SuperGen's schedule of presentations is as follows:
Date Time (PDT) Abstract # and Title Number/Session
Tuesday, 12:30 p.m.- # 1026 - MP470 #A173
Oct. 23 2:30 p.m. suppresses repair of
double-strand breaks Poster Session A
5:30 p.m.- following treatment
7:30 p.m. with DNA-damaging
Wednesday, 12:30 p.m.- # 1038 - The #B140
Oct. 24 2:30 p.m. decitabine-derived
demethylating Poster Session B
5:30 p.m.- dinucleotide, S110
|SOURCE SuperGen Inc.|
Copyright©2007 PR Newswire.
All rights reserved